TY  - GEN
AU  - Xu-Monette, Ziju Y
AU  - Xiao, Min
AU  - Au, Qingyan
AU  - Padmanabhan, Raghav
AU  - Xu, Bing
AU  - Hoe, Nicholas
AU  - Rodriguez Perales, Sandra
AU  - Torres-Ruiz, Raul
AU  - Manyam, Ganiraju C
AU  - Visco, Carlo
AU  - Miao, Yi
AU  - Tan, Xiaohong
AU  - Zhang, Hongwei
AU  - Tzankov, Alexandar
AU  - Wang, Jing
AU  - Dybkær, Karen
AU  - Tam, Wayne
AU  - You, Hua
AU  - Bhagat, Govind
AU  - Hsi, Eric D
AU  - Ponzoni, Maurilio
AU  - Ferreri, Andrés J M
AU  - Møller, Michael B
AU  - Piris, Miguel A
AU  - van Krieken, J Han
AU  - Winter, Jane N
AU  - Westin, Jason R
AU  - Pham, Lan V
AU  - Medeiros, L Jeffrey
AU  - Rassidakis, George Z
AU  - Li, Yong
AU  - Freeman, Gordon J
AU  - Young, Ken H
PY  - 2019
UR  - https://hdl.handle.net/20.500.12105/26147
AB  - PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma. However, whether both PD-1 and CTLA-4 checkpoints are...
LA  - eng
PB  - American Asociation for Cancer Research
KW  - B-CELL LYMPHOMA
KW  - DEATH-LIGAND 1
KW  - CD8 T-CELLS
KW  - PD-1 BLOCKADE
KW  - REGULATORY T
KW  - CTLA-4
KW  - SURVIVAL
KW  - HODKING
KW  - MEMBER
KW  - PROLIFERATION
TI  - Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
TY  - research article
ER  -